Navigation Links
IDRI and Immune Design Corp. Enter License Agreement on GLA Vaccine Adjuvant

SEATTLE, Nov. 20 /PRNewswire/ -- IDRI (Infectious Disease Research Institute) and Immune Design Corp. announced today that they have entered into an agreement pursuant to which Immune Design Corp. is granted a worldwide exclusive license for the research, development, and commercialization of IDRI's Glycopyranosyl Lipid Adjuvant (GLA) technology for products targeting a number of indications. Focusing on its mission to fight infectious diseases of the developing world, IDRI retains worldwide exclusive rights to GLA for selected diseases affecting predominately the developing world. Under the agreement, IDRI will receive an upfront payment, milestones, and royalty payments as well as shares in Immune Design Corp. Further details on the financial terms were not disclosed.

GLA is specifically engineered to improve a vaccine's interaction with the immune system resulting in an enhanced and directed immune response to the vaccine. "We are excited by the promising preclinical results observed so far with GLA," said Chris Clegg, VP Operations and Technology at Immune Design Corp., a Seattle biotech startup focused on novel immunization strategies. "This innovative adjuvant could drive a major shift in the vaccine field."

"We are using GLA in several of IDRI's priority programs but we also think that it has great potential against diseases outside our scope of action," said Curt Malloy, Senior Vice President, Operations and General Counsel, IDRI. "While we retain the necessary rights to pursue our mission against diseases of poverty, revenues generated by this agreement will assist our research and development activities."

As part of its commitment to provide the not-for-profit sector access to its adjuvant technology, IDRI also retains rights to conduct non-commercial research with GLA and will still have the right to provide it to not-for- profit organizations.

Importantly, Immune Design Corp. has adopted a Global Access Plan which addresses accessibility of GLA-containing products the company would develop for diseases of the developing world.

"Creative business agreements with the private sector are critical for the sustainability of our organization but must not be detrimental to the population we are committed to help. We are pleased to sign an agreement with a company that has put in place a Global Access Plan aimed at applying innovation to tackle diseases that disproportionally affect the world's poorest populations," continued Curt Malloy.

About GLA

GLA is a safe and effective vaccine adjuvant formulation that targets a Toll-Like receptor on human dendritic cells, leading to increased and directed immune responses to a vaccine antigen.

About IDRI

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities, IDRI strives to create an efficient pathway bringing scientific innovation from the lab to the people who need it most. For more information, go to

About Immune Design Corp.

Immune Design Corp. is Seattle-based vaccine biotech company working to develop innovative vaccine adjuvants and immunization strategies that specifically target dendritic cells, a critical component of the human system in the initiation of antigen specific immune responses. These novel technologies could create an entirely new generation of both prophylactic and therapeutic vaccines.

SOURCE IDRI (Infectious Disease Research Institute) and Immune Design Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Announces Zook as President
2. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
3. Visualizing asthma-causing immune cells at work
4. Protein-printing technique gives snapshots of immune system defense
5. Peptimmune Presentations at Upcoming Events
6. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
7. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
8. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
9. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
10. EUPROBIO 2008 Presentation to Highlight Latest Immune Research
11. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  ATCC, the premier ... that it has been selected by The Michael J. ... cell lines to academic, pharmaceutical, and biotechnology organizations committed ... the United States , and more ... the United States , and more ...
(Date:10/8/2015)... Texas , Oct. 8, 2015 The 2015 ... of The University of Texas at Dallas. Aziz Sancar ... UT Dallas in 1977, is one of ... how cells continuously monitor and repair damaged DNA on a molecular ... in molecular and cell biology from UT Dallas ...
(Date:10/8/2015)... ST. LOUIS , Oct. 8, 2015 /PRNewswire/ ... that the Cerilliant ® brand within its ... its new bile acid reference standards product line ... the most routinely tested bile acids and their ... materials (CRMs) consist of lithocholic acid, taurocholic acid ...
(Date:10/7/2015)... , Oct. 7, 2015 Boston Scientific ... start of the Boston Scientific Connected Patient Challenge ... in the use of remote patient monitoring to enhance ... and entrepreneurs can submit their ideas and collaborate on ... ). Cambridge, MA ...
Breaking Biology Technology:
... AARUHS, Denmark, July 6 ... the EmbryoScope(TM) Embryo,Monitoring System and EmbryoSlide(TM) tray have ... use in IVF. Unisense Fertilitech A/S also received,the ... installation and servicing of IVF incubators and related,accessories. ...
... Mass., July 6 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: ... amend the $29.5 million of outstanding 8% Senior Convertible Notes ... on July 1, 2009 is effective as of 8:00 a.m. ... Agreements with holders of 87% of the Notes, which is ...
... , REYKJAVIK, Iceland, July 6 Scientists at deCODE genetics ... and the United States today present in the journal ... for basal cell carcinoma (BCC) that affect people with fair ... single-letter variants in the sequence of the human genome (SNPs) ...
Cached Biology Technology:
(Date:10/7/2015)... , October 7, 2015 NXTD ... focused on the growing mobile commerce market and creator ... E. Washington , former long- term executive at American ... --> NXTD ) ("NXT-ID" or the "Company"), ... commerce market and creator of the Wocket® smart wallet ...
(Date:10/5/2015)... October 5, 2015 ... for NXT-ID, Inc. (NASDAQ: NXTD ), a biometric ... --> ) releases the ... NXTD ), a biometric authentication company focused on ... Technology Group ( ) releases the ...
(Date:9/30/2015)... Sept. 30, 2015  With nearly 300,000 Americans living ... new SCIs estimated to reach 12,500 annually, the role ... Resource Services for Independent Living (SCRS-IL) is increasingly ... California opening doors to independence for ... and services, notably assistive technology services and education. ...
Breaking Biology News(10 mins):
... researchers have demonstrated a new and more effective method ... a research advancement that could have major implications ... of death in the Western world. The treatment ... Aaron Baker could allow doctors to bypass surgery and ...
... In a worst-case scenario simulation of a foot-and-mouth disease ... surveillance system and raising a more resilient breed of ... industry should an outbreak of foot-and-mouth disease (FMD) or ... very quickly, such as foot-and-mouth, the best way to ...
... This press release is available in ... biochemical interest given the importance and diversity of the functions ... and serve as fuel for a number of biological systems; ... and, moreover, play a key role in cell processes. Recently ...
Cached Biology News:
... Blunt TOPO PCR Cloning ... designed for cloning and ... PCR products. The pCR4Blunt-TOPO ... Cloning and greater than ...
... 5 ml CELLection Dynabeads (4.5 m) coated ... epithelial antigen EpCAM and DNase Releasing Buffer. ... of epithelial tumour cells directly from blood, ... can be enriched from bone marrow. Enriched ...
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Biology Products: